Analyzing Aadi Bioscience (NASDAQ:AADI) and BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ:BLRX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Profitability

This table compares BioLineRx and Aadi Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLineRx	-90.57%	-163.37%	-34.21%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Volatility & Risk

BioLineRx has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Insider and Institutional Ownership

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares BioLineRx and Aadi Bioscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$28.94 million	0.30	-$60.61 million	($8.80)	-0.30
Aadi Bioscience	$25.07 million	1.64	-$65.76 million	($2.35)	-0.71

BioLineRx has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BioLineRx and Aadi Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	0	1	1	0	2.50
Aadi Bioscience	0	5	0	0	2.00

BioLineRx currently has a consensus price target of $26.00, suggesting a potential upside of 881.13%. Aadi Bioscience has a consensus price target of $1.67, suggesting a potential upside of 0.40%. Given BioLineRx’s stronger consensus rating and higher probable upside, research analysts plainly believe BioLineRx is more favorable than Aadi Bioscience.

Summary

BioLineRx beats Aadi Bioscience on 9 of the 14 factors compared between the two stocks.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.